Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica
Therapeutic monitoring of Ivacaftor, Tezacaftor and Elexacaftor in patients with cystic fibrosis

AUTORI

ABSTRACT

Therapeutic monitoring of Ivacaftor, Tezacaftor and Elexacaftor in patients with cystic fibrosis

The revolutionary new cystic fibrosis (CF) drug combination of ivacaftor (IVA), tezacaftor (TEZ) and elexacaftor (ELX) directly modulates the activity and trafficking of the transmembrane conductance defect (CFTR) regulatory protein underlying CF disease. Limited information is currently available in the literature on plasmatic concentrations of IVA, TEZ and ELX. However, significant interindividual pharmacokinetic variability has been reported in patients receiving the IVA/TEZ/ELX combination, exacerbated by several previously documented drug-drug interactions. Therapeutic drug monitoring (TDM) could therefore be useful in optimizing treatments with CFTR modulators. The purpose of this paper is to provide an overview of currently available information on pharmacokinetics/pharmacodynamics (PK/PD) of the drugs and their relationships to better understand the basis for differences in treatment response. Relevant articles reporting PK/PD data on IVA, TEZ, ELX administered for the treatment of CF were obtained from the PubMed database.

BIBLIOGRAFIA

BIBLIOGRAFIA

1. Elborn JS. Cystic fibrosis. The Lancet 2016;3882519-31.
2. Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci 2017;74:129-40.
3. Gentzsch M, Mall MA. Ion Channel Modulators in Cystic Fibrosis. Chest 2018;154:383-93.
4. Sondo E, Cresta F, Pastorino C, Tomati V, Capurro V, Pesce E, et al. The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. Int J Mol Sci 2022;23:3175.
5. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021;397:2195-211.
6. Castagnola E, Cangemi G, Mesini A, Castellani C, Martelli A, Cattaneo D, et al. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review. Int J Antimicrob Agents 2021;58:106381.
7. Pigliasco F, Cafaro A, Stella M, Baiardi G, Barco S, Pedemonte N, et al. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic fibrosis patients’ plasma by a novel LC-MS/MS Method. Biomedicines 2023;11:628.
8. Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2020;10:1–29.
9. de Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med 2016;4:662-74.
10. Pettit RS, Fellner C. CFTR Modulators for the treatment of Cystic Fibrosis. P T 2014;39:500-11.
11. Guhr Lee TN, Cholon DM, Quinney NL, Gentzsch M, Esther CR. Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment. J Cyst Fibros 2020;19:746-51.
12. Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, et al. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019;5:00082-2019
13. Lommatzsch ST, Taylor-Cousar JL. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Ther Adv Respir Dis 2019;13:1-13.
14. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445–Tezacaftor–Ivacaftor in Patients with cystic fibrosis and one or two Phe508del Alleles. N Engl J Med 2018;379:1612-20.
15. van der Meer R, Wilms EB, Heijerman HGM. CFTR Modulators: Does One Dose Fit All? J Pers Med 2021;11: 458.
16. Kaftrio | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
17. Choong E, Sauty A, Koutsokera A, Blanchon S, André P, Decosterd L. Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: where are we now? Pharmaceutics 2022;14:1674.
18. Tsai A, Wu SP, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with Cystic Fibrosis Transitioning from mono or dual regimens to triple-combination Elexacaftor/Tezacaftor/Ivacaftor. Pulm Ther 2020;6:275-86.
19. Hong E, Almond LM, Chung PS, Rao AP, Beringer PM. Physiologically-based pharmacokinetic-led guidance for patients with cystic fibrosis taking Elexacaftor-Tezacaftor-Ivacaftor with Nirmatrelvir- Ritonavir for the Treatment of COVID-19. Clin Pharmacol Ther 2022;111:1324–33.
20. Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) – Full Text View – ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04602468?term=RECOVER&cond=Cystic+Fibrosis&draw=2&r ank=1
21. The PROMISE Pediatric Study 6 to 11 Years Old – Full Text View – ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04613128?term=PROMISE&cond=Cystic+Fibrosis&cntry=US& draw=2&rank=2
22. Garg V, Shen J, Li C, Agarwal S, Gebre A, Robertson S, et al. Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor. Clin Transl Sci 2019;12:267-75.
23. Schneider EK, Huang JX, Carbone V, Baker M, Azad MAK, Cooper MA, et al. Drug-drug plasma protein binding interactions of ivacaftor. J Mol Recognit 2015;28:339-48.
24. Center for Drug Evaluation and Research: Nda/Bla, Multi-Disciplinary Review and Evaluation, Ivacaftor https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203188Orig1s000Approv.pdf
25. Heijerman HGM, McKone EF, Downey DG, van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940-8.
26. Dagenais RVE, Su VCH, Quon BS. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J Clin Med 2020;10:1-56.
27. Vonk SEM, van der Meer-Vos M, Bos LDJ, Neerincx AH, Majoor CJ, Maitland-van der Zee AH, et al. Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability. Ther Drug Monit 2021;43:555-63.
28. Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to. Lancet Respir Med 2018;6:545-53.
29. Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, et al. Ivacaftor in Infants Aged 4 to. Am J Respir Crit Care Med 2021;203:585-93.
30. European Medicines Agency. ICH Guideline M10 on Bioanalytical Method Validation. Science Medicines Health 2019;44:57 https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf%0Ahttps://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation#current-version-section
31. Lynch KL. CLSI C62-A: A New Standard for Clinical Mass Spectrometry. Clin Chem 2016;62:24-9.
32. D’Avolio A, Cantù M, Gervasoni J, Artusi C, Marinova M, Nonnato A, et al. Bioanalytical method validation of quantitative mass spectrometry based assay: Experimental protocols and regulations. Biochim Clin 2018;42:51-61.
33. Seger C, Salzmann L. After another decade: LC-MS/MS became routine in clinical diagnostics. Clin Biochem 2020;82:2-11.
34. Leung KSY, Fong BMW. LC-MS/MS in the routine clinical laboratory: has its time come? Anal Bioanal Chem 2014;406:2289-301.
35. Habler K, Kalla AS, Rychlik M, Bruegel M, Teupser D, Nährig S, et al. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum. Clin Chem Lab Med 2022;60:82-91.
36. Schneider EK, Reyes-Ortega F, Wilson JW, Kotsimbos T, Keating D, Li J, et al. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1038:57-62.
37. Reyes-Ortega F, Qiu F, Schneider-Futschik EK. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. ACS Pharmacol Transl Sci 2020;3:987-96.
38. Garg V, Shen J, Li C, Agarwal S, Gebre A, Robertson S, et al. Pharmacokinetic and drug-drug interaction profiles of the combination of Tezacaftor/Ivacaftor. Clin Transl Sci 2019;12:267-75.
39. Mehta Z, Kamal KM, Miller R, Covvey JR, Giannetti V. Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database. J Drug Assess 2021;10:62-7.
40. Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Ramakrishnan VR, et al. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy. J Cyst Fibros 2022;21:e141-7.
41. Trimble AT, Donaldson SH. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 2018;17:e13-6.
42. Duckers J, Lesher B, Thorat T, Lucas E, McGarry LJ, Chandarana K, et al. Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review. J Clin Med 2021;10:1527